Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

被引：1
|
作者：
Yoroidaka, Takeshi [1 ,2 ]
Takamatsu, Hiroyuki [1 ]
Yamashita, Takeshi [3 ]
Murata, Ryoichi [3 ]
Yoshihara, Kyoko [4 ]
Yoshihara, Satoshi [4 ]
Ueda, Mikio [3 ]
Nakao, Shinji [1 ]
Matsue, Kosei [5 ]
机构：
[1] Kanazawa Univ, Dept Hematol, Kanazawa, Ishikawa, Japan
[2] Keiju Med Ctr, Dept Internal Med, Nanao, Japan
[3] Keiju Kanazawa Hosp, Dept Internal Med, Kanazawa, Ishikawa, Japan
[4] Hyogo Coll Med, Dept Hematol, Nishinomiya, Hyogo, Japan
[5] Kameda Med Ctr, Div Hematol Oncol, Dept Med, Kamogawa, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126552
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3130
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
    Rocchi, Serena
    Tacchetti, Paola
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    di Giovanni Bezzi, Chiara
    Scalese, Marco
    Dozza, Luca
    Marzocchi, Giulia
    Martello, Marina
    Barila, Gregorio
    Antonioli, Elisabetta
    Staderini, Michela
    Buda, Gabriele
    Petrini, Mario
    Cea, Michele
    Quaresima, Micol
    Furlan, Anna
    Bonalumi, Angela
    Cavo, Michele
    Zamagni, Elena
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 41 - 50
  • [42] Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (KRd) vs. lenalidomide plus dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
    Jakubowiak, Andrzej J.
    Benedict, Agnes
    Panjabi, Sumeet
    Houisse, Ivan
    Campioni, Marco
    Giannopoulou, Andromachi
    Aggarwal, Sanjay
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
    Stewart, A. Keith
    Siegel, David
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej J.
    Miguel, Jesus F. San
    Obreja, Mihaela
    Blaedel, Julie
    Dimopoulos, Meletios A.
    BLOOD, 2017, 130
  • [44] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
    Dimopoulos, Meletios
    Wang, Michael
    Maisnar, Vladimir
    Minarik, Jiri
    Bensinger, William
    Mateos, Maria-Victoria
    Obreja, Mihaela
    Blaedel, Julie
    Moreau, Philippe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [45] Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)
    Derman, Ben A.
    Kubicki, Tadeusz
    Simmons, Heidi
    Afrough, Aimaz
    Zonder, Jeffrey A.
    Grinblatt, David L.
    Anderson, Larry D., Jr.
    Kin, Andrew
    Narula, Sunil
    Rayani, Shayan
    Gurbuxani, Sandeep
    Karrison, Theodore
    Jiang, Ken
    Major, Ajay
    Cooperrider, Jennifer H.
    Jacob, Allison P.
    Jakubowiak, Andrzej J.
    BLOOD, 2023, 142
  • [46] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [47] The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
    Hill, Elizabeth
    Korde, Neha
    Morrison, Candis
    Dew, Alexander
    Carpenter, Ashley
    Epstein, Monica
    Lu, Crystal
    Choyke, Peter
    Mena, Esther
    Lindenberg, Liza
    Landgren, Ola
    Kazandjian, Dickran
    BLOOD, 2020, 136
  • [48] Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
    Zhao, Jessie
    Khong, Tiffany
    Gorniak, Malgorzata
    Khaled, Abir
    Mcdonald, Zac
    Reynolds, John
    Mithraprabhu, Sridurga
    Bingham, Nicholas
    Lim, Suehli
    Wong, Daniel
    Johnston, Anna
    Motorna, Olga
    Murphy, Nicholas
    Quach, Hang
    Yang, Liqiang
    Spencer, Andrew
    HAEMATOLOGICA, 2025, 110 (03) : 764 - 767
  • [49] Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma
    Zhao, Jessie
    Khong, Tiffany T.
    Gorniak, Malgorzata
    Khaled, Abir
    McDonald, Zac
    Reynolds, John
    Wong, Daniel
    Bingham, Nicholas
    Johnston, Anna M.
    Motorna, Olga
    Murphy, Nicholas E.
    Quach, Hang
    Yang, Liqiang
    Spencer, Andrew
    BLOOD, 2023, 142
  • [50] VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
    Piedra, Katrina M.
    Hassoun, Hani
    Buie, Larry W.
    Devlin, Sean M.
    Flynn, Jessica
    Hultcrantz, Malin
    Lesokhin, Alexander M.
    Lu, Sydney X.
    Mailankody, Sham
    Shah, Urvi A.
    Smith, Eric L.
    Landgren, Ola
    Korde, Neha
    Peterson, Tim J.
    BLOOD, 2019, 134
12345